RPL22L1 and glioblastoma: To further confirm whether RPL22L1 directly regulates EGFR/STAT3 pathway to participate in GBM progression, EGFR inhibitor-Gefitinib and STAT3 inhibitor-Stattic were used to treat the cell models.